STOCKS SLIDE EVEN AS NVIDIA SURGES POST-EARNINGS

U.S. economic output hotter than expected in May, dampening rate-cut hopes

Savara Inc. (SVRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

4.1550

-0.1750

(-4.04%)

As of 01:54PM EDT. Market open.

Loading interactive chart...

Business Wire
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa., May 19, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara’s partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP.
Business Wire
Savara Announces New Employment Inducement Grant
AUSTIN, Texas, May 16, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
Business Wire
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
LANGHORNE, Pa., May 09, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update.